Michael Reilly

Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M. Ramanjulu, G. Scott Pesiridis, Jingsong Yang et al. · Nature · 2018 · 803 citations

Systemic Activity, Medicine, Mechanism Of Action +4

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Philip A. Harris, Scott B. Berger, Jae Uk Jeong et al. · Journal of Medicinal Chemistry · 2017 · 464 citations · Full text

Drug Target, Immunology, Cell Death +22

RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer

Wei Wang, Jill M. Marinis, Allison M. Beal et al. · Cancer Cell · 2018 · 245 citations · Full text

Cancer Immunosurveillance, Pancreatic Cancer, Medicine +7

Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2

Alina Mares, Afjal H. Miah, Ian E. Smith et al. · Communications Biology · 2020 · 209 citations · Full text

Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase

SB Berger, Philip A. Harris, Rakesh Nagilla et al. · Cell Death Discovery · 2015 · 145 citations · Full text